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4 CHAPTER 5. MODELLING CYSTIC FIBROSIS AND MUCOCILIARY CLEARANCE
5.1 Mucociliary clearance and cystic fibrosis
This chapter considers the investigation of airway clearance efficiency and dysfunction using rheological
measurements, modelling and simulations of mucus flows. The work is mainly dedicated to healthy
conditions, respiratory epithelium dysfunction subsequently to the consumption of cilia-inhibiting drugs
(eg nicotine) or viral and/or bacterial infections, and cystic fibrosis, although many respiratory diseases
are associated with an altered mucus transport.
The first part of this chapter focuses on the trachea-bronchial tree configuration, the respiratory ep-
ithelium, the dimensioning aspects and the cystic fibrosis pathology. After a factual dimensioning, the
causes and effects of the cystic fibrosis are described. A mathematical modelling is finally built upon the
nature of mucus and its surrounding epithelium environment.
The second part is devoted to the Newtonian case: efficient numerical methods are described. The
algorithm is based on a penalization technique for the moving cilia-shaped geometry, with a one way
coupling (the cell motion is prescribed). The asymptotic analysis and the well-posedness of the math-
ematical mode are discussed. Specific numerical methods are introduced with their inherent features
(convergence, computational time, and memory use) as well as their use when mucociliary clearance is
impaired and mucus viscosity rises.
The third part deals with non-Newtonian aspects. Measurements of cystic fibrosis patient mucus is
described and summarised, leading to its rheological characterisation. Mixing models for non-Newtonian
rheology are based upon a continuous evolution from a low-viscosity Newtonian behaviour, close to the
respiratory epithelium wetted surface, to a strongly shear-thinning behaviour in the mucus layer. Finally,
an extension of the previous numerical method is set up in order to handle the non-Newtonian features,
exhibiting non-reversibility of mucus motion and inefficiency of mucus transport at the cell scale for
cystic fibrosis patient.
5.1.1 Airway wall environment and mucociliary clearance
The mucus in the human respiratory tract is a non-Newtonian fluid that is secreted by the respiratory
epithelium. It protects the respiratory mucosa from dehydration and traps inhaled particles (dust, aller-
gens, carcinogens, micro-organisms, and inflammatory debris). It cleans airways, flowing from either the
trachea-bronchial tree and larynx or nose and pharynx to the oesophagus entry, where it is swallowed (or
expectorated), as displayed in Figure 5.1. An adequate mucus mobility is necessary for a proper airway
clearance. Otherwise pathogens can proliferate and harmful agents can enter the respiratory mucosa.
The airway surface fluid is heterogenous with a near-wall liquid layer containing mostly water and
slightly polymerized mucins and a mucus layer in which completely polymerized mucins cross-link and
build a meshwork, without discontinuity at the microscopic scale. In addition, the airway surface fluid
moves due to the cyclic displacement of cilia. The moving fluid is thus associated with a multi-scale
problem both in time and space.
Respiratory ciliated epithelial cells have a collection of cilia on their lumenal (wetted) surface. Over a
given small airway segment, these cilia beat uniformly in the periciliary fluid (PCF) at a frequency of 4 to
20 Hz, quite different from that of the respiratory cycle (0.2-0.25Hz), during most of their motion cycle.
Mucus motion engendered by beating cilia of respiratory epithelial cells is influenced by its geometrical
and rheological properties. The viscosity of the mucus film (thickness 10-100 µm) increases from its
outer (close to the respiratory epithelium) to inner part (close to the core air flow).
Later in this section, a description is provided of the model that is used for numerical simulations
of the motion of cilia immersed in a heterogeneous fluid with variable viscosity in the direction normal
to the wall. The manifestation of cystic fibrosis is characterised by a stagnation of mucus, allowing a
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Figure 5.1: Multiscale feature of the tracheobronchial tree along its 6 first generations, from the trachea
to the ciliated cells covering a large part of the lung epithelium, taken from Chatelin and Poncet (2013).
proliferation of pathogens agents and thus major infections, whose inflammation effects tend to destroy
the epithelium ciliated cells, leading to sharper stagnation. It results that dangerous bacteria, such as
Pseudomonas aeruginosa releasing pyocyanin, can then colonise the lung. Computing the resulting fluid
displacement enables to study impact of different physical and biological parameters on the mucus trans-
port at the scale of the cell, pointing out mechanisms involved in cystic fibrosis, the major pathological
target of the present work.
5.1.2 The cystic fibrosis pathology
Cystic fibrosis (CF) is a monogenic autosomal recessive disorder. This most frequent life-shortening
genetic disease in the Caucasian population is caused by mutations in the cystic fibrosis transmembrane
conductance regulator (CFTR) gene on chromosome 7. These mutations lead to the production of a
dysfunctional CFTR protein.
The prevalence of the disease varies according to location and ethnic background. CF affects more
than 70,000 people worldwide (30,000 in the USA, 6000 in France). (Hoffman and Ramsey, 2013). It
is observed in 1 infant over 2500 in Europe and North America. The prevalence of cystic fibrosis in the
United States of America is 0.797 per 10000 inhabitants and in average 0.737 in the 27 European Union
countries, with a highest value of 2.98 in the Republic of Ireland (Farrell, 2008).
More than 2000 mutations have been identified in the CFTR gene. Despite the allelic diversity in
this genetic disease, about 85% of White people2 with CF pathology carry at least one copy of the CFTR
2In the general meaning of people from European extraction, including American white people. This aims at being be more
general and rigorous than Caucasian, including intermingling since former Europe.
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gene mutation ∆F508 (F508del CFTR channel variant, cf. Quon and Rowe (2016)). Approximately 4%
of all Whites carry a single cystic fibrosis mutation. Carriers of a single cystic fibrosis mutation do
not generally exhibit any phenotypic abnormality. Two mutations are required to be present for clinical
manifestations of the disease.
In 1969, CF patients in industrialised countries had a mean survival of 14 years. Because of better
understanding of relationships between CFTR gene defects and organ pathophysiology, life expectancy
has improved substantially over the last 40 years. By 2010 the median predicted survival rate approached
40 years (Clancy and Jain, 2012).
The CFTR protein belongs to the large family of adenine nucleotide-binding cassette transporters
consisting of two transmembrane domains, two nucleotide binding domains (NBDs) and a unique regu-
latory domain. This cAMP-regulated anion channel3 is expressed in the airway epithelium, submucosal
glands and many other epithelial organs (eg, biliary and pancreatic ducts) (Mall and Hartl, 2014). It trans-
port anions (mainly chloride and bicarbonate) through the apical membrane of epithelial cells, thereby
creating an osmotic gradient for fluid secretion; the active ion transport is coupled with water efflux. The
basic defect causes an imbalance between secretion and absorption of the epithelial lining fluid rendering
CF airway surfaces vulnerable to dehydration. The induced decrease in the thickness of the airway sur-
face liquid is associated with an increased viscosity and thickening of airway secretions, an obstruction
of airway lumens, a decreased ability to clear inhaled pathogens, and a dysregulated inflammation.
Studies in cultured primary airway epithelia from CF patients carrying a broad spectrum of CFTR
mutations demonstrated that the airway surface liquid is depleted with a collapse of the periciliary layer
and a mucociliary dysfunction (Mall and Hartl, 2014). In the following sections, the very different
nature between periciliary fluid and mature mucus is investigated, and our results confirm the drop of the
mucociliary clearance in the case of PCL collapsing.
Static airway mucus triggers inflammation of epithelial tissue and forms a nidus for bacterial in-
fection. Defective CFTR-mediated bicarbonate transport leads to an acidic airway surface liquid that
results in a decrease in antimicrobial activity (Haq et al., 2015). The epithelial sodium channel (ENaC)
activity is upregulated in CF, which leads to sodium hyper-absorption and contributes to airway surface
dehydration. ENac activation occurs via various mechanisms including the cleavage of its subunit by
endogenous proteases. Indeed, a damaging vicious circle of mucus retention, inflammation, infection
is created (Hoffman and Ramsey, 2013). Many factors mediate the inflammatory response to chronic
bacterial infection such as proinflammatory cytokines (IL-1β, IL-6, IL-8, GM-CSF, TNF-α). Sputum of
CF contains elevated levels of neutrophils and hence exhibits a high concentration of neutrophil-derived
proteases such as neutrophils elastase (Twigg et al., 2015).
Clinically, CF is a complex multi-organ disease that leads to significant chronic sinopulmonary dis-
ease, pancreatic exocrine and endocrine impairments (diabetes), bowel disease, elevated sweat chloride,
and male infertility (Zielenski, 2000). Chronic inflammation and infection may potentiate respiratory
tissue injury, thereby altering progressively pulmonary function. The primary cause of death and long-
term complications among people with CF is chronic bacterial infection in lungs (Yankaskas et al., 2004).
Chronic obstructive lung disease evolves from an early onset of mucus plugging in small airways, chronic
neutrophilic airway inflammation and bacterial infection (Zemanick et al., 2010).
Cystic fibrosis patients battle life-long pulmonary infections. Chronic pulmonary infections con-
tributes to a decline in forced expiratory volume in 1 s (FEV1) of approximately 2% per year. They result
from a limited number of microbial pathogens, among which the most common species are Haemophilus
influenza, Staphylococcus aureus, Pseudomonas aeruginosa, and the Burkholderia cepacia complex. CF
mucus is a specifically favorable niche for growth of Pseudomonas aeruginosa including glycosylation
of airway mucins (Jeffries et al., 2015). There is sufficient evidence that eradication of early infection
3cAMP stands for cyclic adenosine monophosphate, involved in the cAMP receptor proteins (CRP) binding tightly to a
specific DNA.
5.1. MUCOCILIARY CLEARANCE AND CYSTIC FIBROSIS 7
and prevention of chronic Pseudomonas aeruginosa infection is associated with clinical benefit (Doring
et al., 2012).
Until recently, medical treatments for CF exclusively targeted specific sequelae of the underlying
pulmonary disease. For example, intravenous or inhaled antibiotics are administered to limit bacte-
rial infection while macrolides or ibuprofen can be used to reduce inflammation (Doring et al., 2012).
Restoring the impaired clearance of airway secretions in order to optimize microorganisms removal from
airways is one of the major goals of therapy in patients with CF (Kurbatova et al., 2015a).
Current therapies are varied and include: (i) airway clearance to mobilize broncho-pulmonary secre-
tions and interrupt the vicious cycle of inflammation and infection (McShane et al., 2013), (ii) inhaled
dornase which while it does break down DNA and decrease mucus viscosity, has recently been shown to
requires a peripheral small airway deposit (Kurbatova et al., 2015b), (iii) hypertonic saline which may
improve the airway surface hydration (Hoffman and Ramsey, 2013), and (iv) mannitol that can enhance
the airway mucociliary clearance (Aitken et al., 2012; Bilton et al., 2011).
New pharmacotherapy approaches focus on the development of CFTR modulators. These CFTR-
targeted drugs are designed to rescue mutant CFTR function (Mall and Hartl, 2014). Correctors relieve
protein misprocessing due to the most common mutation ∆F508, as it facilitates proper maturation
and delivery to the plasma membrane. Potentiators are CFTR modulators that increase the time CFTR
spends in the open channel configuration and hence chloride transport. They restore airway surface
hydration and mucus clearance. Combined therapies (potentiators and correctors) are now available for
patients (Quon and Rowe, 2016).
Alternative therapeutic approaches to improve airway surface hydration include stimulation or in-
hibition of other channels and transporters involved in apical ion transport to obviate the abnormal ion
transport, solute transfer, pH and airway surface liquid volume generated by dysfunctional CFTRs. Given
hyperactivity of ENaC in CF, inhibitors of the ENac channel or activators of alternative Cl− channels
(CaCC) have recently been investigated as potential therapies (Haq et al., 2015).
5.1.3 Mathematical modelling of lung wall environment
Since the 1970’s and the paper of (Blake, 1972), the mucociliary clearance has been frequently studied
using mathematical modelling combined with numerical and analytic computations – see (Smith et al.,
2008) for a review. Since the publication of this work (2008), several researchers published new re-
searches using 2D modelling (Smith et al., 2007b; Lukens et al., 2010; Montenegro-Johnson et al., 2013;
Lee et al., 2011; Jayathilake et al., 2015; Sedaghat et al., 2016) or 3D modelling (Jayathilake et al., 2012;
Simons et al., 2015; Smith et al., 2007a; Li et al., 2016).
In these papers the airway surface liquid is often considered to have a two-layer structure with con-
stant viscosity in each layer (Lee et al., 2011; Jayathilake et al., 2015; Li et al., 2016). Alternately, other
studies assume a constant viscosity airway surface liquid composed only with one fluid layer (Jayathi-
lake et al., 2012; Simons et al., 2015). The two layer model has also been combined with rheological
behaviours in the upper mucus layer, using a shear-thinning (Montenegro-Johnson et al., 2013; Craster
and Matar, 2000) or a viscoelastic (Mitran, 2007; Sedaghat et al., 2016) modelling.
Regarding numerical analysis, the mucociliary clearance has been computed using various tech-
niques. As the flow modelling leads to a Stokes problem, the Stokeslets method (Cortez et al., 2005)
has been used by several authors (Smith et al., 2007a,b; Lukens et al., 2010; Montenegro-Johnson et al.,
2013). The main drawbacks of this method include the computational cost which grows with the number
of immersed cilia and becomes prohibitive in 3D, as well as the limitation to constant viscosity flows
avoiding the computation of non-linearities such as rheology.
Finite volumes have also been used: a complete discretisation coupled to a finite element beam model
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Figure 5.2: Sketch of the mucus flow on the bronchial wall: the non-homogeneous mucus, which exhibits
a smooth transition between PCL and maturated mucus, is propelled by beating ciliated epithelium cells,
from Chatelin and Poncet (2016).
for cilia has been published (Mitran, 2007), taking into account the fluid-structure interaction. The flow
was successfully computed but this technique requires a large amount of computational resources to solve
resulting linear systems. The immersed boundary method, introduced by Peskin (Peskin, 2003) was also
used in a finite differences context for a parametric study. More recently the immersed boundary method
was coupled with Lattice Boltzmann techniques in order to take into account the two-layer structure of
the airway surface liquid (Li et al., 2016; Sedaghat et al., 2016).
Because the characteristic dimensions of the mucus flow are very small (the mucus film is 10−40µm
height and cilia are 5 − 8µm long), the inertia terms of the Navier-Stokes equations are negligible and
the conservation of momentum can be represented by the linearised Stokes equations. In fact at this
scale inertia terms are vanishing in the Navier-Stokes equations. To simulate the mucociliary clearance
it is important to take into account the cilia motion which propels the airway surface liquid by mean of
fluid-structure interaction. In the following model description, the fluid-structure interaction is assumed
to be “one way”: the force exerted by the fluid on the solid is not computed. In fact this remains an
open problem from a numerical point of view, in particular an eventual beating adaptation (when the
airway surface liquid becomes more viscous for example) has never been studied numerically and, to our
knowledge, only one experimental work was reported (Hill et al., 2010).
The existence of an interface between the periciliary fluid and mucus is debated (Button et al., 2012;
Ehre et al., 2014). In fact, polymerized mucins are released in the periciliary fluid, where they become
progressively hydrated during their crossing of the PCL. Mucins accumulate at a given distance normal to
the wall, giving rise to a mucin-concentrated phase, the mucus. In this region, mucin polymers interweave
and eventually cross-link. The whole set of transformations undergone by mucins during their transport
through the ASL is refered to as maturation in the present text.
These mucins are primarily responsible for the mucus structure and its highly non Newtonian be-
haviour. Near the epithilium the mucin concentration is very low and the airway fluid behaves as a
Newtonian fluid, while further away from the epithilium, the presence of high mucin concentrations re-
sults in non-Newtanian shear thinning behaviour. In order to represent the airway fluid, and particularity
its viscosity, as a continuum instead of a two layer fluid, a variable α is introduced that is a function of
position that varies in a smooth sigmoidal manner between 0 and 1. This function is defined in greater
detail later in this section.
This means that the viscosity can be seen as an ad-hoc function of α: Either µ = Φ(α) in the
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Figure 5.3: Initial profile α used for the cross-linked mucins ratio, defined by Equation (5.3), with respect
to the normalised depth z̃ = z/H , H being the total mucus height.
Newtonian case, detailed in Section §5.2, or µ = Φ(u, α) in the non-Newtonian case, typically
µ = k(α)(2D : D)n(α)−1
for power-law fluids, or a Carreau law for the fluids whose rheology exhibits thresholds, where D is
the strain tensor defined below, detailed in Section §5.3. Then starting from an initial distribution, this
variable α which characterises mucins evolution, is transported and diffused by the mucus flow which
depends on the viscosity. Hence α is the solution to a convection-diffusion equation and it is the natural
to assume that the viscosity is bounded: µ0 ≤ Φ(α) ≤ µ1.
The mathematical problem which has to be solved is the following:
u = ū inside cilia,
−div(2µD(u)) = f −∇p inside fluid,
divu = 0 inside fluid,
∂tα+ u · ∇α− η∆α = 0 everywhere in computational domain,
µ = Φ(α) or µ = Φ(α, u) everywhere in computational domain,
(5.1)
where p is the pressure, µ is the fluid viscosity, f are the external forces and D(u) = (∇u+ (∇u)T )/2
is the strain tensor and ū is the cilia velocity (see computational details in §5.2.2.1). With initial and
boundary conditions yet to be set.
To take into account the motion of immersed beating cilia, the Penalisation method is used (Angot
et al., 1999). It consists in adding an extra term to the conservation of momentum to solve a unique
equation in all the domain, without any distinction between the cilia region B(t) and the fluid region
Ω\B(t) (assuming that Ω is the computational domain). This extra Penalisation term forces the velocity
u to be equal to a prescribed solid velocity ū in the solid region B(t). It transforms the previous problem
into the Penalized Stokes problem or the Stokes-Brinkman problem coupled to the same convection-
diffusion equation generating a non-linear dynamics:
−div(2µεD(uε)) +
1B(t)
ε
(uε − ū) = f −∇pε in Ω,
divuε = 0 in Ω,
∂tα
ε + uε · ∇αε − η∆αε = 0 in Ω,
µε = Φ(αε) or µε = Φ(αε, uε) in Ω,
(5.2)
with 1B(t) the characteristic function of the solid domain and ε the penalty parameter.
This coupled non-linear problem will be solved using dedicated algorithms in order to get powerful
3D simulations and to allow parametric investigations. As detailed in Section §5.2.2 these algorithm are
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based on fast solvers on regular Cartesian grids, so that the computational domain Ω is assumed to be a
rectangular cuboid.
The Stokes problem is completed with a no slip boundary condition at the epithelium surface (where
the periciliary fluid is present), and a free slip boundary condition at the air-mucus interface (which is
assumed to be flat due to a strong surface tension effect (Enault et al., 2010; Chatelin et al., 2016b))
and periodic boundary conditions in the other (proximal and transverse) directions. In the following, let
denotes Γ0 and ΓL, the upper and respectively lower boundaries of the rectangular cuboid computational
domain. Hence Γ0 and ΓL respectively, is the boundary regions where the homogeneous Dirichlet and
homogeneous Neumann respectively, boundary conditions are imposed.
For the convection-diffusion equation, homogeneous Neumann boundary conditions are set at both
epithelium-periciliary-fluid-layer and air-mucus interfaces (meaning on Γ0 ∪ΓL) and periodic boundary
conditions in other directions.
Moreover an initial conditions is provided for the mucins ratio α. A sigmoid profile is used to model
the cross-linked mucins ratio which continuously varies from 0 in the deeper periciliary fluid layer to 1
in the upper mucus layer:
α(x, y, z, t = 0) =
arctan (γ(z − δ))− arctan(−γδ)
arctan (γ(Hz − δ))− arctan(−γδ)
(5.3)
where δ is the ratio between the mucus layer height and the periciliary fluid layer height, and z denotes the
coordinate perpendicular to the epithelium designating position in the fluid. A depiction of Equation (5.3)
is presented in Figure 5.3.
5.2 Newtonian models
A Newtonian fluid behaviour means that the viscosity µ only depends on α, and is independent of u:
In the sets of Equations 5.1 and 5.2, the case µ = Φ(α) is considered. This section is divided in three
part: firstly the well-posedness of Eq. 5.2 is demonstrated, secondly the numerical algorithms dedicated
to the computation of this problem are presented, finally several computations are presented as well as
phenomenological analysis.
5.2.1 Mathematical analysis
In order to perform a mathematical analysis of the problem, we consider first a regularisation of the
domain B(t) described in Figure 5.4. From a technical point of view, this allows the use trace and lifting
theorems in these two domains and to justify the pertinence of the Penalisation method. For the sake of
simplicity the notation B(t) refers to this regularised domain in the whole Section 5.2.1.
Let T > 0 a final time (not necessarily a cilia period). Let Γ = [0, L1]× [0, L2] and Ω = Γ× [0, L]
the domain of study. We denote by Γ0 = Γ × {0} and ΓL = Γ × {L} the lower and upper boundaries
of Ω.
Since the domain B depends on the time parameter t ∈ [0, T ], we need to track this dependency in
the following. We let
O = [0, T ]× Ω the whole domain in time and space coordinates,
Op = {(t, x) ∈ [0, T ]× Ω, ∀t ∈ [0, T ], x ∈ B(t)} the penalized domain,
Ocp =
{
(t, x) ∈ [0, T ]× Ω, ∀t ∈ [0, T ], x ∈ Ω \ B̄(t)
}
= O \ Ōp,
Σ = {(t, x) ∈ [0, T ]× Ω, ∀t ∈ [0, T ], x ∈ ∂B(t) \ ∂Ω} the inner boundary of Op.
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Figure 5.4: The moving domain B(t) models the fixed bronchial wall of the lung and the moving cilia.
In the following we consider the model d) where the boundary ∂B(t) is regular (from Chatelin et al.
(2016b)).
The problem (5.1) is rewritten in these spaces:
u = ū in Op,
−div(2µD(u)) = f −∇p in Ocp,
divu = 0 in O,
∂tα+ u · ∇α− η∆α = 0 in O,
µ = Φ(α) in O
(5.4)
with the initial and boundary conditions described previously:
u = 0 on [0, T ]× Γ0
u = ū on Σ,
u · ν = ∂u1
∂ν
=
∂u2
∂ν
= 0 on [0, T ]× ΓL,
u is periodic on [0, T ]× ∂Γ× [0, L],
∂α
∂ν
= 0 on [0, T ]× (Γ0 ∪ ΓL),
α is periodic on [0, T ]× ∂Γ× [0, L],
α(0, ·) = α0 in Ω,
(5.5)
where η > 0 is the diffusion coefficient, Φ ∈W3,∞(R) and there exists a real number µ0 > 0 a real such
that for all α ∈ R µ0 ≤ φ(α).
According to the modelling, the penalized problem is rewritten such that:
−div(2µεD(uε)) +
1B(t)
ε
(uε − ū) = f −∇pε in O,
divuε = 0 in O,
∂tα
ε + uε · ∇αε − η∆αε = 0 in O,
µε = Φ(αε) in O,
(5.6)
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with its initial and boundary conditions coming straightly from the Equation set (5.5).
uε = 0 on [0, T ]× Γ0,
uε · ν = ∂u
ε
1
∂ν
=
∂uε2
∂ν
= 0 on [0, T ]× ΓL,
uε is periodic on [0, T ]× ∂Γ× [0, L],
∂αε
∂ν
= 0 on [0, T ]× (Γ0 ∪ ΓL),
αε is periodic on [0, T ]× ∂Γ× [0, L],
αε(0, ·) = α0 in Ω.
(5.7)
Finally the following functional spaces are introduced:
Definition 1 Let F(Ω;X) be the set of functions defined on Ω with value in X and
L20(Ω) =
{
v ∈ L2(Ω),
∫
Ω v dx = 0
}
V (Ω) =
{
v ∈ H1(Ω), divv = 0 on Ω, u = 0 on Γ0,
u · ν = 0 on ΓL, u has periodic conditions on ∂Γ× [0, L]}
with the classical H1-norm. Thanks to the generalized Poincaré’s inequality (see (Boyer and Fabrie,
2005) Section III.6), there exist two constants depending only on Ω such that
c1‖∇v‖L2(Ω) ≤ ‖v‖H1(Ω) ≤ c2‖∇v‖L2(Ω).
The following existence and uniqueness results require some regularity assumptions on the obstacle’s
time evolution (H1)-(H2) and on the velocity ū inside the obstacle (H3):
Hypothesis 1 (H1)
• The domain B is an open set in Ω having the uniform C2-regularity property (see (Adams and
Fournier, 2003) Section 4 for the definition) up to the boundary of Ω in order to obtain a periodic
smooth domain,
• ∃(l, l′) ∈ (R+)2 such that 0 < l < l′ < L and Γ × [0, l] ⊂ B ⊂ Γ × [0, l′], i.e. we assume that
the bronchial wall is the fixed domain Γ× [0, l] to which cilia are attached and that the cilia never
reach the top of the domain Ω,
• Ω \ B̄ is an open set in Ω having the uniform C2-regularity property,
• Ω \ B̄ is simply connected.
Hypothesis 2 (H2)
• There exists a function Ψ ∈ C0([0, T ]; C2(Ω)) such that for all t ∈ [0, T ] Ψ(t)|[0,l]×Γ = Id[0,L]×Γ,
Ψ(t)([0, l′]× Γ) ⊂ [0, l′]× Γ and Ψ(t) has periodic boundary conditions on [0, L]× ∂Γ,
• ∀t ∈ [0, T ] Ψ(t) is a C2-diffeomorphism on Ω.
• ∀t ∈ [0, T ] B(t) = Ψ(t, B).
Remark: Here the assumption has been made that the bronchial wall never moves and that the cilia
never reaches the top of the domain. Additionally: Ω \ B̄(t) = Ψ(t,Ω \ B̄).
5.2. NEWTONIAN MODELS 13
Hypothesis 3 (H3)
• ū ∈ C0([0, T ]; H2(B(·)))
• ∀t ∈ [0, T ], div ū(t, ·) = 0 in B(t),
• ∀t ∈ [0, T ] ū(t, ·) fulfills
∀t ∈ [0, T ] ū(t, ·)|Γ0 = 0,
• ∀t ∈ [0, T ] ū(t, ·) has periodic boundary conditions on ∂B(t) ∩ (∂Γ× [0, L]).
Definition 2 (uε, pε, αε) is a weak solution to (5.6)-(5.7) if it fulfills
• uε ∈ Lq(0, T ;V (Ω)), pε ∈ Lq(0, T ; L20(Ω)) with 2 ≤ q ≤ +∞, αε ∈ L∞(0, T ; H2(Ω)) ∩
L2(0, T ; H3(Ω) ∩ H1(0, T ; H1(Ω)),
• for all v ∈ Cc(0, T ;V (Ω)),∫∫
(0,T )×Ω
2µεD(uε) : D(v) dx dt+
1
ε
∫∫
Op
(uε − ū) · v dx dt =
∫∫
(0,T )×Ω
f · v dx dt,
• αε is the solution to 
∂tα
ε + uε · ∇αε − η∆αε = 0 in Ω,
∂αε
∂ν
= 0 on Γ0 ∪ ΓL,
αε has periodic conditions on ∂Γ× [0, L],
αε(0, ·) = α0 in Ω,
(5.8)
• µε = Φ(αε).
Theorem 1 Let 0 < µ0 and ε > 0. Let α0 ∈ H2(Ω) and Φ ∈ W2,∞(R) such that ∀x ∈ R, µ0 ≤ Φ(x).
We moreover assume (H1), (H2), (H3) and that for all T > 0, f ∈ L∞(0, T ; L2(Ω)). There exists then a
unique weak solution (uε, pε, αε) to (5.6) such that
αε ∈ L∞(0, T ; H2(Ω)) ∩ L2(0, T ; H3(Ω)) ∩ H1(0, T ; H1(Ω)),
uε ∈ Lq(0, T ;V (Ω)) for all 2 ≤ q ≤ +∞,
pε ∈ Lq(0, T ; L20(Ω)) for all 2 ≤ q ≤ +∞.
Moreover there exists some constants independent from ε such that uε fulfills
µ0‖D(uε)‖2L∞([0,T ];L2(Ω)) +
1
ε
‖uε − ū‖2L∞([0,T ];L2(B(·)))
≤ C‖f‖L∞([0,T ];L2(Ω))‖ū‖L∞([0,T ];H2(B(·)))
+C ′
(
‖f‖2L∞([0,T ];L2(Ω)) + ‖Φ‖
2
L∞(R)‖ū‖
2
L∞([0,T ];H2(B(·)))
)
.
µ0‖D(uε)‖2L2([0,T ];L2(Ω)) +
1
ε
‖uε − ū‖2L2([0,T ];L2(B(·)))
≤ C‖f‖L2([0,T ];L2(Ω))‖ū‖L∞([0,T ];H2(B(·)))
+C ′
(
‖f‖2L2([0,T ];L2(Ω)) + ‖Φ‖
2
L∞(R))‖ū‖
2
L∞([0,T ];H2(B(·)))
)
.
Definition 3 (u, p, α) is a weak solution to (5.4) with the conditions (5.5) if it fulfills
• for all 2 ≤ q ≤ +∞, u ∈ Lq(0, T ;V (Ω)), p ∈ Lq(0, T ; L20(Ω\B̄(·))) and α ∈ L∞(0, T ; H2(Ω))∩
L2(0, T ; H3(Ω)) ∩ H1(0, T ; H1(Ω)),
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• u = ū in Op,
• (u, p) ∈ Lq(0, T ; H1(Ω \ B̄(·)))× Lq(0, T ; L20(Ω \ B̄(·))), with 2 ≤ q ≤ +∞, is the solution to
−div(2µD(u)) = f −∇p in L2(0, T ; H−1(Ω \ B̄(·))),
divu = 0 in Ocp,
u|Σ = ū|Σ a.e.,
u · ν = ∂u1
∂ν
=
∂u2
∂ν
= 0 on [0, T ]× ΓL,
u has periodic conditions on [0, T ]× ∂Γ× [0, L],
• α is the solution to (5.8),
• µ = Φ(α).
Theorem 2 Under the assumptions of Theorem 1 and with the extra assumption Φ ∈ W3,∞(R), there
exists a unique weak solution (u, p, α) to (5.4)-(5.5). Moreover the weak solution (uε, pε, αε) of (5.6)
converges weakly towards (u, p, α) as ε goes to zero.
We now present the sketches of the proofs of Theorems 1 and 2 and highlight the key points in getting
these theorems.
5.2.1.1 Sketch of the proof of Theorem 1
To prove the existence of a solution to this coupled non-linear problem, consider the introduction of the
sequence (αn, un, pn) defined by:
1. α0 = α0,
2. µn = Φ(αn),
3. (un, pn) is the solution to:
−div(2µnD(un)) + 1B(t)
ε
(un − ū) = f −∇pn in Ω,
divun = 0 in Ω,
un = 0 on Γ0,
u · ν = ∂u1
∂ν
=
∂u2
∂ν
= 0 on ΓL,
un has periodic conditions on ∂Γ× [0, L],
4. αn+1 is the solution to:
∂tα
n+1 + un · ∇αn+1 − η∆αn+1 = 0 in Ω,
∂αn+1
∂ν
= 0 on Γ0 ∪ ΓL,
αn+1 has periodic conditions on ∂Γ× [0, L],
αn+1(0, ·) = α0 in Ω,
We let αn+1 = G(αn).
The study of this recurring sequence leads us to the study of the convection-diffusion equation on one
side and the penalized Stokes equation on the other side:
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Theorem 3 Let η > 0 and u ∈ Lq(0, T ;V (Ω)) for all 2 ≤ q ≤ +∞. Let α0 ∈ H1(Ω). There exists a
unique solution α ∈ L∞(0, T ;H1(Ω)) ∩ L2(0, T ; H2(Ω)) ∩ H1(0, T ; L2(Ω)) to the problem (5.8).
Moreover if α0 ∈ H2(Ω) then α ∈ L∞(0, T ; H2(Ω)) ∩ L2(0, T ; H3(Ω)) ∩ H1(0, T ; H1(Ω)) and there
exists some constants C and C ′ depending only on Ω and η such that for all t ∈ [0, T ]:
‖α(t, ·)‖H2(Ω) ≤ C‖α0‖H2(Ω) exp
(
C ′
∫ t
0
(
1 + ‖u(s, ·)‖2H1(Ω) + ‖u(s, ·)‖
4
H1(Ω) + ‖u(s, ·)‖
8
H1(Ω)
)
ds
)
,
‖α‖L2(0,t;H3(Ω)) ≤ C‖α0‖H2(Ω) exp
(
C ′
∫ t
0
(
1 + ‖u(s, ·)‖2H1(Ω) + ‖u(s, ·)‖
4
H1(Ω) + ‖u(s, ·)‖
8
H1(Ω)
)
ds
)
.
Proof. A classical Galerkin decomposition is performed and energy estimates are made in order to
obtain this result (see also Dautray and Lions (2000) Volume 5 Section XVIII).
Theorem 4 It is assumed that hypothesis (H1), (H2) and (H3) are satisfied. Let µ0 > 0, ε > 0 and
T > 0. Let µ ∈ L∞([0, T ] × Ω) such that µ0 ≤ µ(t, x) a.e. in [0, T ] × Ω. Let f ∈ L∞(0, T ; L2(Ω)).
There exists then a unique weak solution (u, p) to the problem
−div(2µD(u)) +
1B(t)
ε
(u− ū) = f −∇p in [0, T ]× Ω,
divu = 0 in [0, T ]× Ω,
u = 0 on [0, T ]× Γ0,
u · ν = ∂u1
∂ν
=
∂u2
∂ν
= 0 on [0, T ]× ΓL,
u has periodic conditions on [0, T ]× ∂Γ× [0, L],
(5.9)
which fulfills
(u, p) ∈ Lq ([0, T ], V (Ω))× Lq
(
[0, T ]; L20(Ω)
)
for all 2 ≤ q ≤ +∞.
Additionally the following inequalities hold:
µ0‖D(u)‖2L∞([0,T ];L2(Ω)) +
1
ε
‖u− ū‖2L∞([0,T ];L2(B(·)))
≤ C‖f‖L∞([0,T ];L2(Ω))‖ū‖L∞([0,T ];H2(B(·)))
+C ′
(
‖f‖2L∞([0,T ];L2(Ω)) + ‖µ‖
2
L∞([0,T ]×Ω)‖ū‖
2
L∞([0,T ];H2(B(·)))
)
.
µ0‖D(u)‖2L2([0,T ];L2(Ω)) +
1
ε
‖u− ū‖2L2([0,T ];L2(B(·)))
≤ C‖f‖L2([0,T ];L2(Ω))‖ū‖L∞([0,T ];H2(B(·)))
+C ′
(
‖f‖2L2([0,T ];L2(Ω)) + ‖µ‖
2
L2([0,T ];L∞(Ω))‖ū‖
2
L∞([0,T ];H2(B(·)))
)
.
Moreover, if µ ∈ Lq(0, T ; W1,∞(Ω)), with 2 ≤ q ≤ +∞,
(u, p) ∈ Lq
(
[0, T ], H2(Ω)
)
× Lq
(
[0, T ]; H1(Ω)
)
.
and there exists a constant C depending on Ω such that
‖u‖Lq([0,T ];H2(Ω)) +
∥∥∥∥ pµ
∥∥∥∥
Lq([0,T ];H1(Ω))
≤ C‖g‖Lq([0,T ];L2(Ω)),
where g =
1
µ
(
2D(u)∇µ+ f −
1B(t)
ε
(u− ū) + p∇µ
µ
)
∈ Lq([0, T ]; L2(Ω)).
Proof. The existence and uniqueness may be obtained classically thanks to Lax-Milgram theorem. The
regularity is due to classical Stokes regularity results (see for example Boyer and Fabrie (2005)) thanks
to the following rewriting of the equation:
−div2D(u) = 1
µ
(
−2D(u)∇u−
1B(t)
ε
(u− ū) + f −∇p
)
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The ε-independent estimates are obtained by taking u− ũ as test function where ũ(t, ·) is a prolongation
of ū in Ω \ B(t) fulfilling the same boundary conditions as u and the constraint divũ = 0. To prove
the estimates we need time-independent estimates on this prolongation. These ones are obtained thanks
to standard time-independent trace and lifting theorem applied to ū(t,Ψ−1(t, x)) which is well defined
in the non-moving non-deformable domain B thanks to Hypothesis 2. We recover time-independent
bounds thanks to the bounds we have on Ψ.
Both these results prove that the function G is well-defined from E ∩ F in itself with
E = L∞(0, T ; H1(Ω)) ∩ L2(0, T ; H2(Ω)) and F = L∞(0, T ; H2(Ω)) ∩ L2(0, T ; H3(Ω)).
Moreover when α and α′ are solutions of (5.8) with the respective velocity u and u′, u and u′ are solutions
of (5.9) respectively with the viscosity µ and µ′ and µ = Φ(α), µ′ = Φ(α′), we obtain
‖(α− α′)(t, ·)‖2H1(Ω) ≤ C‖u− u
′‖2L2(0,t;H1(Ω))
‖(u− u′)(t, ·)‖H1(Ω) ≤ C‖u′(t, ·)‖H2(Ω)‖(µ− µ′)(t, ·)‖H1(Ω)
‖(µ− µ′)(t, ·)‖H1(Ω) ≤ C(1 + ‖α′‖L∞(0,T ;H2(Ω)))
×‖(α− α′)(t, ·)‖H1(Ω).
This leads to
‖(G(α)−G(α′))(t, ·)‖H1(Ω)
≤ C‖u− u′‖L2(0,t;H1(Ω))
≤ C
(∫ t
0
‖u′(t, ·)‖2H2(Ω)‖(µ− µ
′)(s, ·)‖2H1(Ω) ds
)1/2
≤ C‖u′‖L2(0,t;H2(Ω))‖µ− µ′‖L∞(0,t;H1(Ω))
≤ C‖u′‖L2(0,t;H2(Ω))‖α− α′‖L∞(0,t;H1(Ω)).
where the constant C only depends on T , Ω, f , ū, α0, ε and ‖Φ‖L∞(R).
Since
‖∇µ′(t, ·)‖L∞(Ω) ≤ C‖Φ′‖L∞(R)‖α(t, ·)‖
1/4
H2(Ω)‖α(t, ·)‖
3/4
H3(Ω),
we obtain that µ′ ∈ L8/3(0, T ; W1,∞(Ω)) and then that u′ ∈ L8/3(0, T ; H2(Ω)). Finally
‖u′‖L2(0,t;H2(Ω)) ≤ t1/8‖u′‖L8/3(0,T ;H2(Ω)).
There exists then a time T ∗ ∈]0, T [ such that
‖(G(α)−G(α′))(t, ·)‖L∞(0,T ∗;H1(Ω)) ≤
1
2
‖α− α′‖L∞(0,T ∗;H1(Ω)).
Moreover the time T ∗ only depends on T , Ω, f , ū, α0, ε et ‖Φ‖L∞(R). Thanks to the estimates in Th. 3
and to the estimates in Th. 4 that are independent from α we obtain the existence of a bound on α valid
for all t ∈ [0, T ] and depending only on the data of the problem. Replacing the bounds on α by this new
one, we obtain a smaller time T ∗ valid starting from all t ∈ [0, T ].
Since the function G is a contraction on [0, T ∗] we obtain that the recurring sequence (αn, un, pn)
converges to a weak solution on [0, T ∗], then on [T ∗, 2T ∗] and finally on [0, T ]. Moreover since G is a
contraction and thanks to the estimates we have, we prove the uniqueness of the solution.
5.2.1.2 Sketch of the proof of Theorem 2
The solutions of (5.4)-(5.5) are obtained as limit as ε tends to zero of the solution of (5.6)-(5.7). Accord-
ing to Th. 1 we have that
• αε is bounded independently from ε in the spaces L∞(0, T ; H2(Ω)), L2(0, T ; H3(Ω)) and H1(0, T ; H1(Ω)),
which also implies that αε and ∇αε are bounded in H1((0, T )× Ω),
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• uε is bounded in Lq(0, T ;V (Ω)) for all 2 ≤ q ≤ +∞,
• ε−1‖uε − ū‖2Lq(0,T ;B(·)) is bounded for all 2 ≤ q ≤ +∞.
The ε-independent bounds makes it possible to extract subsequences still denoted (uε, pε, αε) that
converge weakly or weakly-? depending on the bounds and such that uε converges strongly to ū in
Lq(0, T ; L2(B(·))) for all 2 ≤ q ≤ +∞.
One of the key to pass on the limit in nonlinear terms of the equations consists in getting some strong
convergence. This one is obtained thanks to the bound on αε and ∇αε in H1(O) which gives thanks
to Sobolev injection theorem in R4 the strong convergence of a subsequence of αε in W1,q(O) with
2 ≤ q ≤ 4. We now take can take the limit for u in B(t) and in (2) in the domain Ω \ B̄(t) as well as
for αε in (5.8). Finally the uniqueness of the solution can be gained by adapting the estimates that were
used to prove that the function G defined in the Section §5.2.1.1 is a contraction.
5.2.2 Numerical analysis
This section present the numerical algorithms specially developed to compute this mucus flow propelled
by the ciliated epithelium cells. The equation set is rewritten:

∂tα+ u · ∇α− η∆α = 0 in Ω,
µ = Φ(α) in Ω,
−div(2µD(u)) +
1B(t)
ε
(u− ū) = f −∇p in Ω,
divu = 0 in Ω,
(5.10)
where all the quantities have the same signification as in the previous section. The ε indices are removed
in this part to improve the algorithms readability.
The first part of this section brings details on the computation of the cilia motion. The second part
is dedicated to the computation of the mucins’ ratio α (first Equation of (5.10)). The last part details the
computation of the fluid velocity, meaning the Stokes problem (both last Equations of (5.10)).
5.2.2.1 Computation of the cilia beating
The cilia motion is decomposed into two phases: the recovery stroke and the effective stroke. The
recovery stroke, which lasts about 2/3 of the beating period, cilia are bending and moving backward,
close to the bronchial wall and deep in the periciliary fluid layer. During the effective stroke the cilia are
more straight and beat forward and penetrating in the mucus layer.
In order to numerically represent a coherent beating, each cilium is modelled by a filament of 0.3µm
diameter. The motion of this filament is governed by a transport equation set on a parametric curve which
describe the filament centre-line. Equations (5.11) are computed to obtain this, which is presented on the
Figure 5.2.2.1, compared with state of the art experimental and numerical works.
Eventually, the beating remains planar in this study and a small decay can be added between two
adjacent cilia to create a methachronal synchronisation:
∂L
∂t
+ v(t)
∂L
∂θ
= 0 ; P (0, t) = 0 ; L(0, t) = ∂θP (0, t) = g(t) = (2 cos(2πt/T ), 0, 1) (5.11)
where θ is the curve parameter, P (θ, t) is the curve position at time t, L = ∂θP and v(t) = (1 +
8 cos2(π(t + 0.25T )/T ))/T , with T the beating period. To obtain a metachronal synchronisation the
same shift is added to both g and v.
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(a) (b) (c)
(d) (e)
Figure 5.5: Trajectory followed by cilia motion for which each panel is representative of a model posed
in the literature: (a) Fauci and Dillon (2006), (b) Gheber and Priel (1997), (c) Sanderson and Sleigh
(1981) (culture of rabbit cells), and (d) Mitran (2007) (3D elastic beams model) also representative of
the model used in this chapter. Different states of the recovery stroke are displayed in blue, and the states
of the effective stroke are displayed in red.
Equations (5.11) enable the computation of the filament position at any time t. Then the characteristic
function of B(t) the volume occupied by the cilia array can be deduced from the parametric curves, as
well as the cilia velocity field ū(t). These quantities will be used in the following sections.
In all the computations, the counter force applied by the fluid on the solid is not taken into account
in the beating model. To our knowledge, this kind of computation and corresponding beating adaptation
was only studied experimentally (Hill et al., 2010) and coherent modelling remains an open problem.
5.2.2.2 Numerical computation of the mucins convection-diffusion
The first two Equations of (5.10) can be rewritten as an autonomous dynamical system. Indeed the
velocity can be represented a function of the mucins’ ratio through the viscosity, u = F (α):{
∂tα+ F (α) · ∇α− η∆α = 0 in Ω,
µ = Φ(α) in Ω.
(5.12)
The computation of this non-linear convection-diffusion equation can be difficult in a straightforward
manner (finite difference discretisation for example) since two CFL stability conditions arise: one for
each phenomenon (convection and transport). Hence the time step must usually be very small imposing
a large number of iterations and a large number of linear system assembling and resolution, which is
computationally inefficient in 3D.
The viscous splitting (see Beale and Majda (1981)) of Equation (5.12) enables the separation of the
resolution of both operators ∂t + F (α) · ∇ and ∂t − η∆, and allows the independent solution of the two
problems representing each phenomenon: a linear heat equation for diffusion (which is quite common to
solve, particularly when η is small enough to permit explicit computations, which is the case in mucus
framework) and a non-linear convection equation. In the following simulations the splitting introduced
in (Chatelin et al., 2015) guarantees a second order accuracy and permits to alternate the resolution
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of diffusion and convection in order to benefit of diffusion regularising effects after each sub-step of
convection.
For this second one a Lagrangian method is used (Cottet and Koumoutsakos, 2000), the mucin’s ratio
is discretised on a particles cloud:
α(t) =
P∑
p=1
αp(t)δξp(t)vp(t) (5.13)
where ξp and vp are respectively the position and the volume of particle p which carries a mucins’ ratio
αp. Using such a discretisation transforms the convection PDE into a set of ODE’s:
dξp
dt
= u(ξp(t), t)
dαp
dt
= 0
dvp
dt
= 0 (5.14)
in the last equation, particles’ volume do not change since the velocity field is incompressible.
The advantage solving (5.14) instead of a convection PDE is that there is no CFL restriction, so that
large time steps can be achieved. Moreover in (5.14), only the first equation needs to be computed, which
is very computationally efficient and is well suited for 3D computations.
An important feature of the present Lagrangian method is that the velocity field is computed on a
Cartesian grid, where the viscosity (and thus mucins’ ratio) needs to be known. Hence it is necessary
to interpolate these quantities between the grid and the particles. To do that a fourth order interpolation
kernel M ′4 (Monaghan, 1985) is used. It guarantees fast computations since the computational cost is
also linearly proportional to the number of particles (which is identical to the number of grid points) and
accurate results due to the kernel’s third order and regularity.
The operator splitting combined with the Lagrangian computation of convection and accurate inter-
polations with well chosen kernels enables linear computations with respect to the number of grid points.
In order to keep the feature, the computations of velocity also needs to be efficient.
5.2.2.3 An iterative projection for the incompressible Stokes problem
The computation of the Stokes problem at any given time t is considered now. The cilia position and
velocity are already computed (so ū(t) and 1B(t) are known) and the convection–diffusion of α was
achieved so µ(t) is also computed. The last two equations of the set in (5.10) remain to be solved: −div(2µD(u)) +
1B(t)
ε
(u− ū) = f −∇p in Ω,
divu = 0 in Ω\B(t),
(5.15)
To compute this problem an iterative projection method has been developed (Chatelin and Poncet,
2013). This class of methods has been widely used for unstationnary Navier-Stokes equations (Guer-
mond et al., 2006). The principle of all these methods is quite similar: the first step consists in solving
the momentum equation without the pressure gradient. Hence an intermediate velocity field u∗ is intro-
duced that is not required to satisfy the incompressibility condition, divu = 0.
A projection is then computed and the intermediate velocity is corrected in order to obtain a divergence-
free velocity. This is performed by means of the projector P(u∗) = u∗ − ∇ζ where ζ is solution of
−∆ζ = −divu∗ in the whole domain, and satisfying the boundary condition ∂ζ/∂n = u · n.
The main drawback of these methods is that the projector is usually computed by solving a Poisson
problem with an homogeneous Neumann boundary condition. After the correction, the velocity field
usually does not satisfy the original boundary condition (Guermond et al., 2006).
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That the boundary conditions are not satisfied becomes more pronounced at low Reynolds numbers.
This is the reason that projection methods developed for Navier-Stokes flows cannot be applied to the
Stokes equations (Chatelin, 2013). To overcome this problem a new iterative projection method was
introduced in (Chatelin and Poncet, 2013). The algorithm is presented as:
1. Initialisation: u∗0 = u0 is provided.
2. Fixed point iterations, where i denotes the iteration number:
(a) u∗i is known, as well as ui = P(u∗i ) and ∇ζi = u∗i − P(u∗i ),
(b) Prediction : u∗i+1 is the solution to: − µ∆u∗i+1 +
1B(t)
ε
(u∗i+1 −∇ζi − u(t)) = f + (2D(ui) + divu∗i )∇µ in Ω
u∗i+1 = g −∇ζi on ∂Ω
(5.16)
where the last term of (5.16) comes from the substitution u∗ = u+∇ζ.
(c) Correction: compute ζi+1, the solution to a Poisson problem: −∆ζi+1 = −divu
∗
i+1 in Ω
∂ζi+1
∂n
= 0 on ∂Ω
(5.17)
and project: ui+1 = P(u∗i+1) = u∗i+1 −∇ζi+1 .
(d) Repeat 2a-2b-2c and increment i until convergence is satisfied.
3. The solution to the Penalised Stokes problem is ui+1.
This algorithm only involves the computation of elliptic problems. In particular the computation of
the projector can be achieved using a FFT or multigrid solver (Swarztrauber and Sweet, 1975; Adams,
1989) which are very powerful. Indeed using a regular Cartesian grid the structure of the discretised
operator is known a priori and no matrix assembling nor linear system resolution is required. Hence the
computational cost is quasi linear with respect to N , the number of computational grid points, that is
to say with a complexity O(N logN). Furthermore it guarantees an accurate computation of boundary
conditions, immersed solid velocity, invicid velocity and non-homogeneous effects.
In order to conserve this computational efficiency, which is very attractive for 3D computations,
the penalised Stokes Equation (5.16) and the projection using FFT need to be computed with a similar
computational cost. The next section describes a numerical method for the penelised Stokes equation
using only FFTs.
5.2.2.4 A Sherman–Morrison–Woodbury approach to compute Penalised Poisson problems
To compute the Penalised Poisson problem of at the first step of the previous iterative projection, a special
algorithm has been developed (Chatelin and Poncet, 2014), based on the algebraic perturbation relation:
the Sherman–Morrison–Woodbury formula (Hager, 1989). This formula enables the computation of the
inverse of an invertible perturbed matrix:(
A+ ETCE
)−1
= A−1 −A−1ET
(
C−1 + EA−1ET
)−1
EA−1 (5.18)
The problem to solve (first step of the previous iterative projection) can be rewritten as follow (gath-
ering all the term depending on previous iteration k in the RHS):{
−∆u+ cu = f in Ω
u = 0 on ∂Ω
(5.19)
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Name Value
Cilia length 8 µm
Cilia diameter 0.3 µm
periciliary fluid viscosity (ηPCF ) 0.001 Pa.s
Viscosity ratio (β = ηML/ηPCF ) 100
Viscosity transition stiffness (γ) 10
Transition length (δ) 7 µm
airway surface liquid height (Hz) 13 µm
Beating frequency 10 Hz
Mucins diffusion (ν) 10−11m2.s−1
Table 5.1: Reference parameters for the numerical simulations (gathered from (Fahy and Dickey, 2010;
Sanderson and Sleigh, 1981; Smith et al., 2008; Thiriet, 2012))
where c represents the Penalisation term and iteration subscripts were removed. Hence this problem can
be seen as a Poisson problem perturbed in the cilia volume. Then, applying a generic discretisation to
(5.19), it can be exactly rewritten as an algebraic perturbation problem and the SMW formula can be
applied:(
A+ ETCE
)
U = F ⇐⇒ U = A−1F −A−1ET
(
C−1 + EA−1ET
)−1
E A−1F (5.20)
In this equation, each product involving A−1 can be achieved without matrix assembling and inver-
sion by using the Poisson solver. The key point is to invert the term inside parenthesis without matrix
inversion and assembling, which is achieved with an iterative GMRES method. The global algorithm
reads in four steps:
1. Solve the Poisson problem AW = F
2. Solve QZ = EW with Q = C−1 + EA−1ET . This is performed by means of the GMRES
method, that requires the product evaluation Z → QZ as follows:
(a) Solve the Poisson problem AΘ = ETZ
(b) Set QZ = C−1Z + EΘ
3. Solve a last Poisson problem AY = ETZ
4. Update the solution U = W − Y
Steps 2a and 2b are computed at each Krylov iteration so the total number of Poisson problems to
solve is 2+NKry whereNKry is the typical size of the Krylov space. The other steps are negligible from
a computational point of view: as C is a diagonal matrix its inverse is immediately computed, restriction
and inclusion matrices E and ET are deduced from 1B(t) and never assembled.
5.2.3 Numerical computations of the mucus propelled by ciliated epithelium
The overall algorithm, presented in the previous sections have the following convergence features :
• A O(
√
ε) convergence order for the Penalisation method, which is a standard result (Carbou and
Fabrie, 2003).
• A second order temporal accuracy, obtained with the splitting algorithm (Chatelin et al., 2015).
• A second order spatial accuracy which is given by the fast FFT solver (Swarztrauber and Sweet,
1975).
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Figure 5.6: Snapshots of the mucus propulsion by a carpet of 25 ciliated epithelium cells at five different
instants. The colormap shows the magnitude of the first component of the velocity field. At the begin-
ning of the computation the cross-linked mucins ratio α is initialised according to Equation (5.3). The
periciliary fluid viscosity is equal to that of water (10−3Pa.s) and the viscosity of the mucus is 0.1Pa ·s.
An isosurface of α = 0.5 is presented in green. In black, a passive particle clearly shows that the mucus
is transported toward trachea. Panels (a) to (e) are snapshots at times t = 3.33 × 10−2 s, t = 0.77 s,
t = 0.28 s, t = 0.29 s and t = 0.88 s.
• A very negligible mass diffusion in particle transport and interpolation processes (Chatelin and
Poncet, 2013)
The first simulation presented involves a simplified epithelium cell composed of 25 cilia regularly
arranged as a 5×5 array. Snapshots are presented in Figure 5.6. This simulation was performed with the
parameters gathered of Table 5.1. This figure presents an isosurface of cross-linked mucins ratio, velocity
magnitude in the proximal direction and a passive black particle, advected by the flow. On average, this
passive tracer travels forward (in the proximal direction to the trachea) which shows that the mucociliary
clearance is effective.
The second simulation, presented on Figure 5.7 presents the mucociliary transport with a carpet of
300 cilia, still using the parameters of Table 5.1. This computation presents the effect of the metachronal
synchronisation (when a shift is added in the beating between adjacent cilia, creating the metachronal
wave) for a large number of cilia. This figure shows that the metachronal wave travels backward, gener-
ating a positive first velocity component wave in the mucus layer whereas the velocity is zero or lightly
negative in the periciliary fluid layer.
As in the previous figure, the passive black particle clearly shows that the upper part of the airway
surface liquid travels forward, thus the mucociliary clearance is efficient. This simulation shows that a
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Figure 5.7: Snapshots of the mucus propulsion by a carpet of 300 ciliated epithelium cells at five different
times. Colormap and fluid features are the same as in Figure 5.6, except that the isosurface level is
α = 0.65. Panels (a) to (e) are snapshots at times t = 6.67 × 10−3 s, t = 0.2 s, t = 0.23 s, t = 0.35 s
and t = 0.5 s.
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“leading cavity” effect is created when cilia are in recovery stroke, maximising the mucociliary transport.
These results, also reported in Hussong et al. (2011) using simplified simulations, help to validate the
present methodology.
5.2.4 Phenomena analysis
In order to quantify the mucociliary clearance efficiency, the mean velocity of the mucus layer is averaged
over several beating periods T :
U =
1
3THxHy(Hz − δ)
∫ 3T
0
∫ Hz
δ
∫ Hy
0
∫ Hx
0
ux(x, y, z, t)dxdydzdt (5.21)
Using different parameter sets, this quantity enables the comparison between different simulations
(Chatelin and Poncet, 2016). This can be used in the identification of the meaningful parameters and
can help to identify the influence of pathological situations in mucociliary transport. In this study, the
following meaningful parameters were identified:
• The beating frequency 2π/T is an important parameter of the modelling. Indeed, as a consequence
of the time-dilatation of the quasi-static Stokes equations, the mucociliary transport varies linearly
with respect to this parameter. This result was also reported using 2D computations with a bi-fluid
modelling (Lee et al., 2011).
• It was also demonstrated that the cilia length is very important. In fact when cilia are too small
the mucociliary clearance is deteriorated. This paper shows that it can be divided by ten if cilia
are 3µm long instead of 9. It was demonstrated that the most efficient result is obtained when
cilia penetrate the mucus layer during the effective stroke and remain in the periciliary fluid layer
during the recovery stroke. This result confirms this assumption formulated in Liron and Rozenson
(1983) and contradicts the results of Fulford and Blake (1986).
• As expected, the viscosity ratio between mucus and periciliary fluid has also a great importance:
when the mucus becomes highly viscous, the mucociliary clearance is also deteriorated, it can
be divided by two when the mucus is 1000 times more viscous than periciliary fluid layer. It is
important to notice that the most efficient mucociliary clearance is not obtained for a ratio of 1
(meaning an airway surface liquid only composed of periciliary fluid) but when the mucus is about
10 times more viscous. It means that the mucociliary clearance permits to handle the accumulation
of cross-linked mucins in the mucus layer, ensuring a good protection of the airways.
• The transition length δ between mucus and periciliary fluid layer is also very important. It is the
equilibrium between both these characteristic lengths which leads to the penetration (or not) of the
cilia tips in the mucus during the effective stroke. In particular when this transition length is too
small (this is representative of the case in which nearly all of the airway surface liquid is composed
of mucus) the mucociliary clearance can be divided by 2.5.
• Finally the transition stiffness γ between the periciliary fluid layer and the mucus is also an impor-
tant parameter. It means that to achieve an efficient mucociliary clearance two layers have to be
clearly identified. This also enables the penetration in the mucus only during the effective stroke.
5.2.
N
E
W
TO
N
IA
N
M
O
D
E
L
S
25
Source Alias Rheometer Pathology Additional information n k n* k*
Puchelle et al. (1987) CR Chronic airway 0.18 18.38
hypersecretion
Jeanneret-Grosjean et al. (1988) HL6 MµR Healthy - - 0.19 14.13
HL7 Healthy Control - - 0.20 15.49
Healthy After administration of Atropine - - 0.20 70.79
Healthy After administration of Diazepam - - 0.15 20.42
Rubin et al. (1990) MµR Healthy taken from endotracheal tube - - 0.20 10.96
at the end of a surgery
CF - - 0.29 23.99
Zayas et al. (1990) HL8 MµR Healthy - - 0.22 13.18
LS Without cancer, without obvious airway infection - - 0.17 7.08
HS Without cancer, without obvious airway infection - - 0.15 18.62
XS Without cancer, without obvious airway infection - - 0.16 6.92
C Without obvious airway infection - - 0.15 11.75
Moores et al. (1992) CR COPD infective exacerbation 0.04 15.00 0.13 1.71
Dawson et al. (2003) CFL5 CR CF - 0.05 18.00 0.17 7.34
Nielsen et al. (2004) CR CF - 0.27 5.40 0.163 12.45
Redding (2008) MµR Br Idiopathic bronchiectasis (children) - - 0.20 6.84
CF Children - - 0.16 33.43
CB Adults - - 0.14 53.03
Innes et al. (2009) CR Healthy Sputum induction performed with - - 0.18 3.34
nebulized 3% saline for 20 minutes
Serisier et al. (2009) HL9 CR Healthy Sputum induction with 4.5% hypertonic saline - - 0.48 0.35
CFL1 CF Clinically stable - - 0.41 0.54
COPD Clinically stable - - 0.34 1.29
Suk et al. (2009) CR CF - 0.16 2.42
Daviskas et al. (2010) CR Br Clinically stable - - 0.41 36.31
CR Br Clinically stable - - 0.45 24.76
- After repetitive voluntary coughing -
Schuster et al. (2013) CR Healthy taken from endotracheal tube - - 0.16 12.97
at the end of a surgery
Tomaiuolo et al. (2014) CFL2 CR CF FEV1% > 50% 0.23 2.18 0.18 1.40
according to FEV1 CFL3 CF 30% < FEV1% < 50% 0.21 12.81 0.17 2.25
CFL4 CF FEV1% < 30% 0.26 6.87 0.16 2.42
Tomaiuolo et al. (2014) CR CF S. aureus 0.20 3.04 - -
according to main colonization CF P. aeruginosa 0.17 14.10 - -
CF B. cepacia and S. maltophila 0.14 10.86 - -
Table 5.2: Mucus rheological characterization : power-law parameters. CR: Classical rheometer, MµR: Magnetic µ-rheometer. CF: Cystic Fibrosis, Br: Bronchiec-
tasis, COPD: Chronic Obstructive Pulmonary Disease, CB: Chronic Bronchitis, LS: Light Smokers, HS: Heavy Smokers, XS: ExSmokers, C: Cancer. FEV1%:
ratio of the Forced Expiratory Volume in 1 second (FEV1) to the Forced Vital Capacity (FVC).
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5.3 Rheology of mucus and non-Newtonian models
5.3.1 Rheometry data on lung mucus from the literature
Looking at studies concerned with rheological characterisations of pulmonary mucus, two points are
noticeable. First, two kinds of equipment are used: as expected, classical rheometers, but also magnetic
micro-rheometers. Secondly rheological characterisations are often limited to the determination of the
dynamic storage modulus (G′) and loss modulus (G′′) for two frequencies, 1 and 100 rad/s, which are
supposed to be characteristic frequencies of mucociliary clearance and cough clearance respectively
(App et al., 1998).
5.3.1.1 The different measurement methods
Considering rheological measurements on lung mucus, there are almost as many studies with magnetic
micro-rheometers as ones with classical rheometers. The magnetic micro-rheometer uses either a single
steel bead (App et al., 1998; Redding, 2008) or multiple magnetite particles (Edwards and Yeates, 1992;
Ziemann et al., 1994) positioned in a few µL of fluid and oscillated by means of an electromagnetic field
to obtain a sinusoidal force. In the first case, the bead diameter ranges from 50 to 100µm while particles
dimension ranges from 2 to 6µm in the second case. The motion of the single bead or of the particles
embedded in the fluid is then quantified, generally by fast image processing techniques: See King and
Macklem (1977) and Ziemann et al. (1994) for the detail of rheological parameters extraction. Note
that King and Macklem (1977) has incorporated Thomas and Walters (1966) results to take into account
elasticity of the fluid. This technique has largely been used for respiratory mucus (Jeanneret-Grosjean
et al., 1988; Rubin et al., 1990; App et al., 1998; Zayas et al., 1999; Redding, 2008).
The main advantage of the micro-rheometer lies in the very small volume of fluid that is necessary
(few µL). This is of particular interest for mucus that are generally not available in large quantities except
for major pathologies such as cystic fibrosis. It is important to note that in general, mucus type fluids
are not homogenous anf that larger sample volumes would allow a more representative measurement of
the global rheological behaviour and a better precision. Additional drawbacks are that only oscillatory
experiments are possible with such a micro-rheometer and that the flow is not a simple shear flow as it is
theoretically required for rheometry (Barnes et al., 1989).
Classical rheometry is predominantly used in recent years (Sanders et al., 2000; Dawson et al., 2003;
Nielsen et al., 2004; Innes et al., 2009; Serisier et al., 2009; Daviskas et al., 2010; Tomaiuolo et al.,
2014). It is performed using most of the time controlled-stress rheometer equipped with cone and plate
geometry or parallel plates geometry. These are generally chosen to minimise the fluid volume: small
diameter /small angle for the cone (1 or 2o), or small gap for parallel plates (between 50 and 250µm
when specified).
Note that the term “micro-rheology” may be confusing as it is also used to represent length scales
below 0.1–0.3 µm, for instance to examine virus or nano-particle motion through mucus (Sanders et al.,
2000; Dawson et al., 2003; Lai et al., 2009; Schuster et al., 2013). Viscosity experienced by these objects
is close to that of water and this is linked to the mesh size of the network structure of mucus which is
larger than or similar to the object size. Nevertheless for the mucus clearance process, larger length scales
are relevant. So the viscosity that has to be considered here is a macroscopic one which is anticipated to
greatly exceed the viscosity of water and is associated to a complex rheological behaviour.
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5.3.1.2 Mucus rheology from literature
A general presentation of mucus, its role, its chemical chemical structure and its physiological properties
can be found in Cone (2005). Reviews of their rheological properties are presented by Yeates et al.
(1997) and Picout and Ross-Murphy (2003). Considering human airway mucus, there is very little data
available in literature for steady state viscosity while data for dynamic viscosity η′ = G′/ω or complex
viscosity |η∗| = |G∗|/ω, from oscillatory measurements, are more numerous. When it is reported, the
measurement temperature is 20◦C, 25◦C or 37◦C. This might appear as a large discrepancy but variances
caused by temperature differences are small compared to those from the non-Newtonian feature, as it was
demonstrated by Tomaiuolo et al. (2014).
When a rheogram is proposed, all authors agree to recognise a strong shear thinning behaviour. Some
authors (Moores et al., 1992; Dawson et al., 2003; Suk et al., 2009) observed a tendency to a Newtonian
plateau at low shear rates with a transition towards power-law behaviour between 0.1s−1 and 1s−1,
depending on authors. On the other hand Yeates et al. (1997) did not observe any trend to a plateau
although exploring shear rate from 0.2s−1 upwards. The same observation was made by Puchelle et al.
(1985, 1987) for shear rate starting from 0.01s−1 and 0.1s−1 respectively. In the shear thinning region,
the behaviour can be modelled by a power-law τ = kγ̇n, where τ and γ̇ are the shear stress and the shear
rate respectively, k the fluid consistency and n the power-law index. Values for k and n given in literature,
or extracted from literature data, are reported in Table 5.2. Note the low values of the power-law index
(between 0.04 and 0.26) which are characteristic of a strong shear-thinning behaviour.
Thixotropy is the property of a fluid to show a reversible decreasing viscosity when submitted to
a constant shear rate (i.e. observation of a decreasing shear stress as a function of time). Note that
thixotropy is sometimes confused with shear-thinning, although rheological definition is unambiguous
(Picout and Ross-Murphy, 2003). Thixotropy leads to a hysteresis phenomena that has been observed
on viscosities measured at increasing shear rates followed by measurements at decreasing shear rates
(Nielsen et al., 2004; Tomaiuolo et al., 2014). Conversely, note that hysteresis is not necessarily evidence
of thixotropy because elasticity may also be responsible for hysteresis, especially when the characteristic
time of the fluid is comparable to or larger than the time scale of measurement. Mention of the character-
istic time for mucus are not numerous in the literature: Besseris and Yeates (2007) gave 42s for canine
tracheal mucus, while, for human mucus, Moores et al. (1992) obtained 20s from creep tests and Nielsen
et al. (2004) estimated it of the order of thousands of seconds from oscillatory measurements. Academic
thixotropy measurements were realized by Puchelle et al. (1985, 1987) who observed a shear stress over-
shoot after a shear rate step. Such an overshoot is linked to elasticity, but successive experiments with
decreasing rest time after previous shearing show a decreasing overshoot. This has allowed Puchelle et
al. to identify the presence of thixotropy for a reconstituted mucus (Puchelle et al., 1985) and a native
mucus (Puchelle et al., 1987).
A few authors have identified a viscoplastic behaviour with a yield stress varying between 0.05 to
0.26Pa (Edwards and Yeates, 1992) until 100 Pa (Silberberg, 1983). For instance this last value was
used by (Craster and Matar, 2000) to analyse numerically the surfactant transport of mucus film in the
pulmonary airways. More recently, Broughton-Head et al. (2007) proposed a value of 14 Pa for cystic
fibrosis mucus. As far as we know, these are the only publications identifying a viscoplastic behaviour
and giving yield stress values. This can be connected to specific rheometers used or to the way rheological
characterisations were conducted.
On the other hand, elasticity has been clearly identified in literature. This is due in part to the
widespread use of the magnetic micro-rheometer which is restricted to small-amplitude oscillatory shear
experiments. The storage modulus G′(ω) and the loss modulus G′′(ω) are the most common data en-
countered in the literature at the two frequencies ω = 1 rad/s and ω = 100 rad/s. The moduli G′ and
G′′ are the imaginary and real parts of the complex modulus G∗ = τ/γ, where γ is the deformation. A
phase shift between shear stress and shear rate γ̇, i.e. a non-zeroG′ value, demonstrate the elastic feature
of the fluid. Data are expressed in terms of modulus or, in equivalent form, using the complex modulus
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Figure 5.8: Comparison between consistency k and power-law index n issued from viscosity curves and
estimations (k∗, n∗) issued from the Cox-Merz rule. Note that each point from literature is a mean value
while a point marked “this study” corresponds to one of the tested mucus. The solid line denotes the
identity.
G∗ and the loss tangent tg δ = G′′/G′, or G′ and the so-called dynamic viscosity η′ = G′′/ω. The
specific two values of the frequency, 1 and 100rad/s, are often reported in literature because they were
proposed by some authors (Jeanneret-Grosjean et al., 1988; Zayas et al., 1990; Shah et al., 1996; App
et al., 1998; Zayas et al., 1999; Innes et al., 2009) to define a mucociliary clearability index (convention-
ally called MCI) and a cough clearability index (CCI), which quantify respectively the clearability by
normalized ciliary function (using values at 1 rad/s) and by cough (using values at 100 rad/s). As far
as we know, the first time a mucociliary clearability index is proposed was by Jeanneret-Grosjean et al.
(1988). MCI and CCI are then mentioned in Zayas et al. (1990). Note that these index were also used
by Tomaiuolo et al. (2014) at a frequency of 10 rad/s for CCI . These indexes are of particular interest
in the evaluation of and quantification of the influence of pathologies on the mucus clearance for smokers
and lung cancer patients (Zayas et al., 1990, 1999), for asthma (Innes et al., 2009), and for the influence
of treatments or physiotherapy (Shah et al., 1996; App et al., 1998).
In the study of the flow of mucus, the essential parameter is the viscosity. One can ask whether the
Cox-Merz rule is sufficient to evaluate η(γ̇) using oscillatory measurement data. The Cox-Merz rule
is considered as very useful when only linear viscoelastic data are available (Bird et al., 1977). It is
expressed as:
| η∗(ω) |=
√
η′(ω)2 + η′′(ω)2 = η(γ̇)|γ̇=ω (5.22)
The Cox-Merz rule is well-adapted for polymer solutions with entangled network structure. It fails
(with generally | η∗ |> η) for cross-linked systems or for highly concentrated entangled systems. Cross-
linked polymers are characterised by non-existence of a Newtonian plateau for η(γ̇) and a weak evolution
of elastic and viscous modulus with frequency. Based on such observations numerous authors think that
mucus is of cross-linked type (Puchelle et al., 1985; Innes et al., 2009; Schuster et al., 2013) but Yeates
et al. (1997) developed arguments for an entangled “sliplinked” strand system. Looking at Table 5.2,
there are only six cases where the power-law parameters (n, k) and (n∗, k∗) (from power-law model
applied to η∗(ω) available data) can be estimated and compared. The consistency k is underestimated
when assimilated to k∗ for five of the six cases, while no real tendency can be observed on (n, n∗) data
(see fig. 5.8). This point will be re-examined later.
Information related to pathology are presented in Figure 5.9. For this representation, the rheological
variables | G∗ | and tan δ were chosen as they are often considered as relatively independent while G′
and G′′ are not (Jeanneret-Grosjean et al., 1988; King, 1980). Nevertheless, | G∗ | varies with respect
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Figure 5.9: Rheological parameters G∗ and tan δ (measured at 1rad/s) for different pathologies. Sym-
bols: same as in Table 5.2. All cases with simple symbols concern studies with patients in a stable
state. Symbols with a surrounding square indicate study for patients in exacerbation or study without
information.
to viscosity while tan δ compares viscous and elastic response of the fluid (with tan δ infinite for purely
viscous fluids). Concerning healthy patients, it is noticeable that the two points corresponding to the
lower | G∗ |-value were obtained after nebulisation with a saline solution to induce sputum. This proba-
bly led to the thinning of the mucus and also helps to explain these lower values as well as the large tan δ
value. Although these comparisons have to be considered cautiously because conditions differ between
studies (how mucus is taken and prepared, how rheological characterisations are conducted for exam-
ple). It is noteworthy to point out that that mucus samples from patients with pathology do not strongly
differ with samples from healthy patients (except in some cases of bronchiectasis and COPD). On this
graph, the majority of data corresponds to stable patients, or healthy, one case corresponds to exacerbated
situation and no information is given for five cases. In a study on rheological properties of CF mucus,
(King, 1981) proposed to classify mucus from their visual aspect in three categories (linked to the nature
and to the degree of infection): mucoid, muco-purulent and purulent. Comparing G′ and η′ for three
frequencies, he observed that rheological properties for mucoid and muco-purulent human CF mucus are
similar to control canine tracheal ones while purulent mucus show higher values and a diminution of tg δ
(i.e. higher elasticity). This was also underlined by Deneuville et al. (1997); Lopez-Vidriero and Reid
(1978). Although this distinction between mucus seemed no longer considered for several years, more
recent studies have confirmed the interest of this observation, using stable/exacerbated distinction rather
than visual criteria : Serisier et al. (2009) and Tomaiuolo et al. (2014) for CF sputum, and Tabatabaei
et al. (2015) for COPD.
5.3.2 Mucus sample analysis and rheological results
5.3.2.1 Mucus samples collecting
Consecutive adult patients with cystic fibrosis (CF) bronchiectasis (Br) were recruited when admitted
in the regional adult CF center of Toulouse. After information and oral consent, sputum samples were
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CFM1 CFM2 CFM3a CFM3b CFM4 CFM5 CFM6
n 0.20 0.39 0.32 0.39 0.30 0.30 0.23
k 5.80 0.45 1.24 1.60 3.53 2.37 4.22
Tc(s) > 20  20  20 – > 20 > 20 ≈ 20
n∗ 0.17 0.07 0.25 0.04 0.15 0.23 0.24
k∗ 24.6 3.08 0.98 8.45 6.32 9.92 1.82
CFM7 CFM8 CFM9 CFM10 CFM11 BM12
n 0.21 0.23 0.37 0.36 0.22 0.40
k 3.10 3.53 0.51 2.17 4.75 1.43
Tc(s) ≈ 100 ≈ 100 ≈ 50 ≈ 30 > 20 ≈ 80
n∗ 0.17 0.20 0.28 0.20 0.21 0.25
k∗ 6.43 3.28 2.20 1.85 2.92 1.95
Table 5.3: Power-law parameters, relaxation time and power-law parameters from Cox-Merz rule from
collected samples. (n, k) data are from Chatelin et al. (2016a).
collected under supervision of a chest physiotherapist. Patients were classified as either having a stable
status or having and exacerbation. The classification of exacerbation represented an increased cough or
an increased bronchorrhea or purulence sputum, and/or an increased dyspnea, and/or a tiredness and/or
a loss of weight). Sputum were frozen at −20oC before rheological analysis.
5.3.2.2 Mucus sample analysis
In this study rheological characterisations were evaluated on a Mars III rheometer (Thermo Sc.) equipped
with a cone and plate geometry (1◦ angle, 35mm diameter) which requires 0.2mL of fluid. Measurements
were conducted at 37◦C. The lower plate Peltier system for temperature regulation was completed by
a sample hood that was custom made in-house with a specific temperature regulation and wet sponges
to saturate the measuring chamber and prevent evaporation of the sample. As previously mentioned,
samples were stored frozen at −20◦C. The influence of freezing on the rheological properties of mucus
has previously been investigated by Rubin et al. (1990), Sanders et al. (2000), Gastaldi et al. (2000) and
Serisier et al. (2009) for different conditions (temperature, freezing duration). These authors all conclude
that congelation does not affect rheological behaviour. This result was confirmed in the current study on
three samples that were characterized when fresh and again at 21 or 31 days under frozen conditions.
Mucus were thawed keeping them in a water-ice mixture just before and during measures to prevent
degradation (Sanders et al., 2000).
Once a sample was loaded in the rheometer, the following protocol was followed: an initial dynam-
ical strain sweep at a fixed frequency of 1 Hz was conducted to determine the linear domain. Then the
storage modulus G′(ω) and the loss modulus G′′(ω) were determined using an oscillatory frequency
sweep for a fixed strain in the linear domain (between 1% and 3% according to the sample). After that,
the sample was submitted to very large deformationsin which the viscosity η(γ̇) was determined by a
steady-shear flow test for shear rates in the range 10−3s−1 to 103s−1. Careful attention was paid to
reaching the steady state regime for cases with low shear rate values. Additional measurements were
sometimes conducted to examine the stability of a sample. A power-law model η = kγ̇n−1 (k: consis-
tency, n: power-law index) was used to fit the rheological data. When the sampled volume was sufficient,
two or three different tests were performed.
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Figure 5.10: Viscosity curves, on the left for mucus CFM7: ‘S’ standing for Sample and ‘Meas.’ for
measurement. Measurements on sample 4 were done after a sequence of large amplitude oscillations
(LAOs) at 300% and 1Hz during 60 minutes. Right picture shows rheograms for three different mucus.
5.3.2.3 Rheological results
Initially a few samples were used in order to determine the measurement strategy. Then fifteen mucus
samples were analysed. Two of the samples were rejected because they gave rise to a large dispersion in
viscosity and modulus values. Thirteen mucus were then considered for data analysis.
To examine thixotropy, experiments were conducted that were based on the observation of the shear
stress overshoot after a shear rate step (similar to those of Puchelle et al. (1987)). Because the results
of those experiments were found to be inconclusive, another approach has been adopted. On one of the
mucus (CFM7), viscosity measurements were conducted on four samples while on a fifth one, a large
amplitude (300%, i.e. far from the linear domain) oscillatory sequence (LAOs) was first applied during
60 minutes. After that a viscosity measurement was done. The results are reported in Figure 5.10-a. The
viscosities for samples S1, S2, S3 and S5 reveals the variability between samples and between measure-
ments. Figure 5.10) reports the data indicating which of the three measurement numbers are reported.
For measurements 2 and 3 (Meas. 2 and Meas. 3), only small amplitude oscillatory measurements were
conducted before on this sample (strain sweep and/or frequency sweep). No specific classification linked
to solicitations to which the sample was previously submitted appears in these results, especially after
a strong and long solicitation such as 60 minutes of LAOs (S4, Meas.2 and Meas. 3). Figure 5.10-b
presents steady-state shear viscosity curves established for mucus CFM2, CFM6 and BM12. For each
of them, two or three measurements were conducted thus illustrating both the dispersion observed on a
same mucus and the variability observed between mucus. The dispersion observed on all these series are
similar, which implies that thixotropy is weak and comparable here to the natural dispersion arising from
heterogeneity of samples and from the measurement difficulties.
As previously reported (Chatelin and Poncet, 2016), a strongly shear-thinning behaviour is observed
all over the shear rate range studied. Mucus samples were characterised on a wide shear rate range
starting at 10−3s−1 and no trend to a Newtonian plateau was observed, corroborating the results of
Puchelle et al. (1985, 1987) and Yeates et al. (1997). Note that the same observation can be made on the
viscosity calculated from the Cox-Merz rule, i.e. from data for which the fluid has only been subjected
to small deformations (in this case, the equivalent shear rate range covered is [0.01s−1; 30s−1]). This
behaviour is commonly associated with cross-linked polymers and is sometimes referred to as “yield
stress” behaviour (leading to the commonly used term “viscoelastic gel”). While data for shear rates as
low as 10−3s−1 were conducted, the τ(γ̇) curves did not show any trend to a yield stress.
A power-law model was fitted on the shear rate range [0.1s−1; 100s−1] which is representative of
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Figure 5.11: Dynamic oscillatory shear tests (filled symbols : elastic modulus G′, hollow symbols:
viscous modulus G′′). (a) strain amplitude sweep, (b) frequency sweep.
shear rate involved in the flow. The power-law parameter (index n and consistency k) are reported in
Table 5.3 (from Chatelin and Poncet (2016) for (n, k) values). The power-law indexes n are in the range
0.2 to 0.4 and are thus similar to values obtained by Puchelle et al. (1987), Nielsen et al. (2004), Suk
et al. (2009) and Tomaiuolo et al. (2014) while Moores et al. (1992) and Dawson et al. (2003) observed
lower n-values. Values of consistency k, and then for viscosity are also similar. The large shear rate
range explored in this study gives an appropriate description of viscosity for the present study, which
means this range is coherent with the shear rates observed in the numerical simulations.
Oscillatory measurements are presented in Figure 5.11. Strain sweeps are presented for four mucus
(Fig. 5.11-a) and clearly show a large linear domain as it extends until 5 to 10%. Figure 5.11-b presents
the storage modulus G′ and the loss modulus G′′ from a frequency sweep. These curves clearly display
the viscoelastic character of mucus: exploring the low frequencies (until 10−3Hz, i.e. more than 1000s
for a point), the G′(ω) and G′′(ω) curves present the typical viscoelastic frequency-evolution: although
slightly varying with frequency, these curves cross each other at a frequency ωc which allows the deter-
mination of a characteristic times Tc = 1/ωc. This cross frequency was not reached for each mucus, but
values or estimation are reported in Table 5.3. They range from 20s up to 100s or more, thus highlighting
the precautions to be taken for measurements that must correspond to a steady regime.
As a great number of studies only consider dynamic measurements, it is of interest to examine the
validity of steady shear viscosity estimated from these measurements. For polymer solutions and polymer
melts, the Cox-Merz rule (Eq. 5.22) is considered as an acceptable way to evaluate viscosity. Parameters
k∗ and n∗ of the power-laws fitted on |η∗(ω) | data are reported in Table 5.3 and presented in Figure 5.8-a
and b for k vs k∗ and n vs n∗ respectively.
Results are slightly different from those extracted from literature: for consistency, which can be
regarded as viscosity at 1s−1, k∗ is similar or higher than k. This is coherent with what is known on the
validity of the Cox-Merz rule which overestimate the shear viscosity (Picout and Ross-Murphy, 2003).
Concerning the power-law index, n∗ is similar to n for five cases but significantly lower for others, i.e.
indicates a more shear-thinning behaviour. Considering both k∗ and n∗, this signifies that the difference
between dynamic viscosity and shear viscosity becomes increasingly large with decreasing shear rates:
considering the viscosity at 1s−1, a relative differences of more than 100% is observed 7 times out of 13.
For a shear rate of 0.01s−1, this score reaches 9 out of 13.
Nevertheless, a power-law index of 0.2 (resp. 0.4) leads to changes in viscosity in a ratio 6.3 (resp.
4) over an order of magnitude on shear rate. It follows that variations of viscosity in a flow such that
which is considered here are most of the time considerably larger than variations emanating from the
discrepancy induced by the Cox-Merz rule. In this sense, dynamic measurements for viscosity can be
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Figure 5.12: Aliases from Tables 5.2 and 5.3. Blue and red markers are Cystic Fibrosis samples re-
spectively from the literature and from our study, while green markers denote healthy samples from the
literature.
taken into consideration when shear viscosity cannot be measured.
5.3.3 Mathematical modelling of the rheology and related numerical analysis
As presented in the previous section, mucus exhibits a non-Newtonian behaviour with shear-thinning
effects. The previous section shows that the power-law is a good representation of the rheological be-
haviour of the mucus. As presented in Table 5.3 the exponent of the shear rate is negative (since n was
identified below unity). From a mathematical and a computational point of view, this can be critical
because the viscosity can tend toward infinity when the shear rate tends toward zero, in particular when
the flow is at rest (at any given time and given point) or when any infinitely small fluid volume undergoes
a solid-like displacement (i.e. with no strain).
In order to avoid the singularity that arises at rest, a limitation of the viscosity at low shear rates
is introduced. Furthermore, the aqueous polymer mixture cannot be less viscous than its solvent, which
means that at high shear rate, the decreasing viscosity has a lower bound at the PCL viscosity (Newtonian
with viscosity equal to that of water at 20oC). Among the different constitutive laws, the Carreau model
is interesting as it is a power-law with two Newtonian limits:
η(γ̇) = ηmin + (ηmax − ηmin)
[
1 + (βγ̇)2
]n∗−1
2 (5.23)
The transition between the plateau with viscosity ηmax, and the power-law behaviour occurs at γ̇ =
1/β. So β can be used for smoothing and avoid the singularity at rest, and therefore can be chosen as
large as wanted. The parameter ηmax is then calculated from the power-law parameters and the β-value.
In our simulations, β is set to 4000s−1, this corresponds to a shear rate transition lower than the lowest
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shear rates explored in mucus rheometry. This β value was sufficient to ensure that the results do not
depend on the regularisation process. On the other hand, viscosity is limited to values higher than ηmin
(water viscosity here) for high shear rates.
Furthermore, the previous non-Newtonian results are given for the mucus layer and the periciliary
fluid layer remains a Newtonian fluid whose viscosity is equal to that of water. Hence it is necessary to
model viscosity as a function of α: with a transition from the Newtonian periciliary fluid when α = 0 to
the non-Newtonian Carreau model when α = 1.
From a numerical point of view, the only difference is the definition of the viscosity which is now a
function of the velocity, through the shear rate γ̇(u) = (2D :D)1/2. The problem to solve is the same as
(5.10), except the second equation which is replaced by an α-dependant rheological constitutive equation
(Chatelin et al., 2016a):
η(γ̇) = Φ(u, α) = ηPCF + (η0(α)− ηPCF )
[
1 + (βγ̇)2
]n∗(α)−1
2 (5.24)
where
η0(α) = ηPCF
(
k∗ML
ηPCF
)α
βα(1−n
∗
ML) and n∗(α) = α · n∗ML + (1− α) (5.25)
As mentioned previously, these equations state that the viscosity of the mucus cannot be smaller than
the periciliary fluid viscosity, even when the shear rate tends toward infinity. They are introduced in
Equation (5.2), which reads:
−div(2η(γ̇)D) +
1B(t)
ε
(u− ū) = f −∇p and divu = 0 in Ω (5.26)
with the adequate boundary and initial conditions, coupled to the model followed by α, either the trans-
port Equation (5.12) or the stratified law displayed on Figure 5.3.
Hence the computational algorithm presented in Section §5.2.2 is slightly modified. Indeed the
computation of α remains identical whereas a non-linearity appears in the conservation of momentum
equation. This non-linearity is treated “explicitly” in the same fixed point as the projection iterations.
Hence the only modification is in the step 2b of this algorithm (see §5.2.2.3) which becomes a multi-
criteria fixed-point algorithm. Denoting ηi = Φ(ui, α) the new step 2b reads:
−ηj∆u∗j+1 +
1B(t)
ε
(u∗j+1 −∇ζj − u(t)) = f + (2D(uj) + divu∗k)∇ηj (5.27)
The rest of the algorithm presented in Section 5.2.2 remains unchanged. In particular the SMW
approach (see §5.2.2.4) is still applicable to compute (5.27) as well as the operator splitting and the
Lagrangian computation of the convection of the mucin’s ratio.
5.3.4 Medical outcomes
Regarding the Newtonian case, a parametric study was performed to investigate the influence of the rhe-
ological parameters on the mucociliary clearance efficiency (Chatelin et al., 2016a). The same quantity,
defined by Equation (5.21), is computed for this discussion. In Figure 5.12, the results are presented for
169 (n∗ML, k
∗
ML) pairs using the α-dependant rheological constitutive equations previously introduced.
The mucus samples presented in the Section 5.3, on Tables 5.2 and 5.3, are also reported on this phase
cartography.
This figure clearly shows that the mucociliary transport does not evolves linearly with respect to the
power-law coefficients n∗ and k∗. This is a direct consequence of the non-linearities of the modelling.
In fact, it not meaningful to discuss viscosity variations for shear-thinning fluids and these power-law
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Figure 5.13: Impact of PCL rarefaction (δ decreasing from 0.7 et 0.3) on mucus mean velocity in per-
cent of healthy mucus velocity. The healthy velocity is the mean velocity of HL6-8 for δ = 0.6. The
Moderately impacted region corresponds to the samples CFM3,4,5,9,10, the Strongly impacted region
corresponds to the samples CFM1,6,7,8,11, and the Extremely impacted region corresponds to the sam-
ples CFL5.
coefficients are more significant. It is noteworthy to observe that that the CF mucus generally take lower
consistency values k than healthy mucus samples, as well as lower power-law exponent n (except for the
HL9).
Figure 5.12 shows that a drop of 6–15% mobility may be observed for the CF mucus than in the
healthy samples. Even if this decrease is not spectacular, it is sufficient to trigger pathological infections
such as Pseudomonas aeruginosa or Burkholderia cepacia (Eberl and Tümmler, 2004). Moreover it
is important to notice that even if the datum of HL9 (Serisier et al., 2009) is very different from other
healthy mucus (Jeanneret-Grosjean et al., 1988; Zayas et al., 1990), the mean mucus velocity remains
similar and we can conclude that the associated mucociliary transports are comparable.
Figure 5.12e demonstrates that the shear-thinning behaviour has a very strong effect: when the
power-law exponent decreases to 0.2 (which is the measured value for 5 samples), the mucociliary trans-
port is highly deteriorated. This is counterintuitive, but it is the consequence of a higher velocity during
the recovery stroke in the mucus layer, since the “apparent viscosity” decreases.
From a clinical point of view, two types of CF mucus can be distinguished: stabilized and decompen-
sated (with acute secondary infections). The mucus of same patient was sampled in both states: two days
after hospitalisation (CFM3a, decompensated) and after 17 days of treatment, combining antibiotics and
steroids (CFM3b, stabilised). The computations presented in Figure 5.12 clearly show an increase in the
mucociliary transport for this patient, thus we conclude that the treatment was beneficial.
Finally, similarly to the Newtonian case, several computations were performed for different heights
of periciliary fluid and still 169 values of (n∗ML, k
∗
ML) pairs – see Chatelin et al. (2016a) for details. It was
demonstrated that this pericilary fluid height has a very important effect on the mucociliary transport with
up to a 21% decrease in mucus mean velocity. This parameter represents the effect of a variable CFTR
deficiency (Thornton and Sheehan, 2004; Ehre et al., 2014) and it also shows the lack of mucociliary
clearance in cystic fibrosis, allowing pathological proliferations.
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This effect had been summarized in Figure 5.13, where three groups are displayed:
• A group k∗ = 1.5, n∗ = 0.35, corresponding to a centre of gravity of samples CFM3-5,9,10,
which is moderately impacted by PCL rarefaction,
• A group k∗ = 4, n∗ = 0.25, corresponding to a centre of gravity of samples CFM1,6-8,11, which
is strongly impacted by PCL rarefaction, decreased up to−13% compared to healthy cases, which
means a −6% due to lack of mucociliary clearance efficiency, made worse by −7% due to PCL
height decrease.
• A location k∗ = 8, n∗ = 0.15, corresponding to case CFL5 reported in Dawson et al. (2003),
corresponding to a situation extremely impacted by PCL rarefaction, with a decrease of −23%
compared the healthy configuration.
5.4 Concluding remarks
The lung is resistant to damages following exposure to pathogens and more or less toxic chemical pollu-
tants in inhaled air. Airway mucus represents the first line of defense. Inhaled particles (allergens, dust,
micro-organisms, and cellular debris) trapped in the mucus gel are removed from the respiratory tract
by the mucociliary clearance. Mucus cleans airways, as it flows from either the tracheobronchial tree or
upper airways toward the pharynx, where it is swallowed (or expectorated).
Ciliary motions enable mucus propulsion in the human respiratory tract. The beating cycle of respi-
ratory cilia is composed of 3 phases: a rest phase, a recovery stroke, and an effective stroke. During the
recovery stroke, cilia (height 1–7 µm according to the location in the respiratory tract and investigators)
sweep backward remaining close to the epithelium and immersed in the periciliary fluid without contact
with mucus. Cilia of a patch of ciliated cells form a coordinated beating cluster (beating frequency 10–20
Hz). The cilium tips impact mucus during a short phase of its beating cycle. Cilia are more rigid in the
forward power stroke and more flexible in recovery stroke in preparation for the next effective stroke.
The present mathematical model of airway surface liquid dynamics relies on a heterogeneous fluid
that moves due to beating deformable cilia. The airway surface liquid nature evolves continuously in both
composition and rheology from the periciliary fluid to the mucus. Within the near-wall fluid surrounding
the deformable cilia, the mucin polymers released by the epithelium further hydrate. Once they reached
a certain distance normal to the wetted surface of the respiratory epithelium, which is slightly lower than
the cilium height, mucin polymers accumulate, engendering a mucin-concentrated phase. In this region,
mucin polymers interweave and eventually cross-link. This evolving nature of the airway surface liquid
affects its rheology. For example, for a airway surface liquid thickness of 12 µm and cilium height of 8
µm, the thickness of the periciliary fluid and mucus are equal to 7 and 5 µm, respectively.
The rheological behaviour is associated with two parameters of interest, the fluid consistency index
k and the power law index n that describes the difference between the two asymptotic behaviours (µ0
and µ∞) and the slope of the shear rate–viscosity curve between these two asymptotic behaviours.
The numerical model is combined with an experimental study of the rheology of sputum from cystic
fibrosis patients. The proposed robust numerical method handle variations in shear rate and viscosity
of more than 5 orders of magnitude. It leads to a cartography that allows to discuss major issues on
defective mucociliary clearance observed in cystic fibrosis during periodic check-up of the disease in a
steady clinical state (i.e., in the absence of infection exacerbation) for prognosis.
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